November 4, 2011
Kaken Pharmaceutical’s consolidated sales increased to ¥43,692 million, up 1.9% from a year earlier, driven by strong sales of its mainstay products such as the joint function improving agent Artz (hyaluronate sodium). Generics also contributed to growth in overall sales...read more